Side effects of chemotherapeutic oculo-toxic agents: A review

Clinical Eye and Vision Care

Volumn 12, Issue 3-4, 2000, Pages 113-117

  Maino, Dominick M ^a   Tran, Saly ^a   Mehta, Faresh ^a  

^a ILLINOIS COLLEGE OF OPTOMETRY   (United States)

Author keywords

Cancer; Chemotherapeutic agents; Oculo visual toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CARMUSTINE; FLUOROURACIL; INTERFERON; METHOTREXATE; MITOMYCIN C; NILUTAMIDE; SURAMIN; TAMOXIFEN;

ACCOMMODATION; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; DRY EYE; EYE TOXICITY; HUMAN; PHOTOPHOBIA; QUALITY OF LIFE; VISUAL IMPAIRMENT;

EID: 0034546496     PISSN: 09534431     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0953-4431(00)00053-9     Document Type: Article

References (46)

1. Ocular complications of systemic cancer chemotherapy
2. Influence of myleran on cell proliferation in lens epithelium
3. Clinical and morphological side effects of busulfan (Myleran) treatment
4. Sicca syndrome in a patient with toxic reaction to bulsulfan
5. Antiandrogens: A summary review of pharmachodynamic properties and tolerability in prostate cancer therapy
6. Androgen receptor antagonists (antiandrogens): Structure activity relationships
7. Ocular toxicity of anandron in patients treated for prosthetic cancer
8. Suramin an anticancer drug with a unique mechanism of action
9. Toxic keratopathy associated with suramin therapy
10. Suramin keratopathy
11. Ocular symptoms and signs of associated suramin sodium treatment for metastatic cancer of the prostate
12. Methyl CCNU and adriamycin combination therapy
13. Ophthalmic and central nervous system complications following intracarotid BCNU(carmustine)
14. Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas
15. Intra-arterial BCNU chemotherapy for treatment of malignant gliomas of the central nervous system
16. Ocular toxicity associated with high dose of carmustine
17. Ocular side effects of cancer chemotherapy
18. Optic neuroretinitis in association with BCNU and procarbazine therapy
19. Visual abnormalities following nitrosurea treatment
20. Ocular toxicity of systemic chemotherapy with megadoses of carmustine and mitomycin
21. Visual system toxicity following intra-arterial chemotherapy
22. Poston G: p53 protein overexpression and response to biomodulated 5-fluorouracil chemotherapy in patients with advanced colorectal cancer
23. Excessive lacrimation from flurouracil treatment
24. Cicatrical ectropion secondary to 5-flurouracil therapy
25. Ankyloblepharon associated with systemic 5-flurouracil treatment
26. Sclerosing canaliculitis after 5-flurouracil breast cancer chemotherapy
27. Serious corneal complications of glaucoma filtering surgery with postoperative 5-flurouracil
28. Complications of subconjunctival 5-flurouracil following glaucoma filtering surgery
29. Ocular complications with high dose interferon alpha in chronic hepatitis
30. Retinal complications and plasma C5a levels during interferon alpha therapy for chronic hepatitis C
31. Neurotoxic and other side effects of high dose interferon in amyotrophic lateral sclerosis
32. Vetiligo associated with alpha interferon in a patient with chrons active hepatitis C
33. The effect of mitomycin C on activities of carbonic anhydrase and ATPase of the ciliary body epithelium in rabbit
34. Ocular toxicity of mitomycin in rabbit
35. Toxic effects of mitomyicin C on cultured corneal keratocytes and endothelial cells
36. Oestrogon receptors and antagonism of steroid hormone action
37. Tamoxifen blocks chloride channels: A possible mechanism for cataract formation
38. Tamoxifen retinopathy: Does it really exist?
39. Long-term tamoxifen citrate use and potential ocular toxicity
40. Tamoxifen and ocular toxicity
41. Clear evidence that long term, low dose tamoxifen treatment can induce ocular toxicity: A prospective study of 63 patients with cancer
42. Ocular toxicity of tamoxifen
43. New approaches to cancer chemotherapy with methotrexate
44. Topical application of methotrexate for inhibition of corneal angiogenesis
45. Ocular irritation from high dose methotrexate therapy: Pharmacokinetics of drug in the tear film